Atopic Dermatitis - Pipeline Review, H2 2014 th
On 19 September 2014
Summary Atopic Dermatitis - Pipeline Review, H2 2014, provides an overview of the Atopic Dermatitiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on latestage and discontinued projects.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-Atopic-Dermatitis-Pipeline-Review-H2-2014-124323 Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope - The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industryspecific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Table of Content List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Atopic Dermatitis Overview 11 Therapeutics Development 12 Pipeline Products for Atopic Dermatitis - Overview 12 Pipeline Products for Atopic Dermatitis - Comparative Analysis 13 Atopic Dermatitis - Therapeutics under Development by Companies 14 Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes 20 Atopic Dermatitis - Pipeline Products Glance 21 Late Stage Products 21 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Clinical Stage Products 22 Early Stage Products 23 Atopic Dermatitis - Products under Development by Companies 24 Atopic Dermatitis - Products under Investigation by Universities/Institutes 29 Atopic Dermatitis - Companies Involved in Therapeutics Development 30 Bristol-Myers Squibb Company 30 Johnson & Johnson 31 Kyowa Hakko Kirin Co., Ltd. 32 Valeant Pharmaceuticals International, Inc. 33 Daiichi Sankyo Company, Limited 34 Merck & Co., Inc. 35 Taisho Pharmaceutical Co., Ltd. 36 Takeda Pharmaceutical Company Limited 37 Novartis AG 38 Amorepacific Corporation 39 Chugai Pharmaceutical Co., Ltd. 40 Eisai Co., Ltd. 41 LEO Pharma A/S 42 Mitsubishi Tanabe Pharma Corporation 43 Pfizer Inc. 44 Celgene Corporation 45 Bayer AG 46 AlbireoPharma 47 NicOx S.A. 48 Nuvo Research Inc. 49 Yungjin Pharm Ind. Co., Ltd. 50 Regeneron Pharmaceuticals, Inc. 51 HanAll Biopharma Co., Ltd. 52 AnGes MG, Inc. 53 Provectus Biopharmaceuticals, Inc. 54 R-Tech Ueno, Ltd. 55 Paloma Pharmaceuticals, Inc. 56 Upsher-Smith Laboratories, Inc. 57 Foamix Ltd. 58 Anacor Pharmaceuticals, Inc. 59 AnaptysBio, Inc. 60 IMMD Inc. 61 Circassia Holdings Ltd. 62 Oxagen Limited 63 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Melior Discovery, Inc. 64 Grupo Ferrer Internacional, S.A. 65 Xencor, Inc. 66 Welichem Biotech Inc. 67 ChemoCentryx, Inc. 68 Vitae Pharmaceuticals, Inc. 69 arGEN-X BV 70 SWITCH Biotech LLC 71 Promius Pharma, LLC 72 Celsus Therapeutics Plc 73 Pharis Biotec GmbH 74 Vicore Pharma AB 75 Otsuka Holdings Co., Ltd. 76 LegoChem Biosciences, Inc 77 Fountain Biopharma Inc. 78 Pergamum AB 79 VivaCell Biotechnology Espana S.L. 80 Brickell Biotech, Inc. 81 NeoPharm Co., Ltd. 82 Herantis Pharma plc. 83 Creabilis SA 84 Polyrizon Ltd. 85 sterna biologicals Gmbh & Co KG 85 Dermira Inc. 86 Istituto Italiano di Tecnologia 87 Thesan Pharmaceuticals, Inc. 88 ChironWells GmbH 89 Pharmedartis GmbH 90 Atopic Dermatitis - Therapeutics Assessment 91 Assessment by Monotherapy Products 91 Assessment by Target 92 Assessment by Mechanism of Action 96 Assessment by Route of Administration 100 Assessment by Molecule Type 102 Drug Profiles 105 KTG-001 - Drug Profile 105 DAN-2728 - Drug Profile 106 dupilumab - Drug Profile 108 roflumilast - Drug Profile 110 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
tofacitinib - Drug Profile 113 apremilast - Drug Profile 117 CT-327 - Drug Profile 119 ustekinumab - Drug Profile 121 PH-10 - Drug Profile 124 DPK-060 - Drug Profile 126 cobamamide - Drug Profile 127 OC-459 - Drug Profile 128 LEO-29102 - Drug Profile 130 MRX-6 - Drug Profile 131 WBI-1001 - Drug Profile 132 Small Molecule for Immunology, Ophthalmology, Oncology and Dermatology - Drug Profile 134 AN-2898 - Drug Profile 136 S-414114 - Drug Profile 138 mapracorat - Drug Profile 140 DRM-02 - Drug Profile 142 E-6005 - Drug Profile 143 fevipiprant - Drug Profile 144 TA-7906 - Drug Profile 146 QGE-031 - Drug Profile 147 SB-011 - Drug Profile 149 CIM-331 - Drug Profile 150 OPA-15406 - Drug Profile 151 KHK-4577 - Drug Profile 152 PDI-192 - Drug Profile 153 Drug for Atopic Dermatitis and Eczema - Drug Profile 154 DFD-06 - Drug Profile 155 BPR-277 - Drug Profile 156 mometasone furoate - Drug Profile 157 Furestem-AD - Drug Profile 158 BMS-981164 - Drug Profile 159 IMD-0354 - Drug Profile 160 ZPL-3893787 - Drug Profile 161 XmAb-7195 - Drug Profile 162 MK-8226 - Drug Profile 163 LEO-39652 - Drug Profile 164 Small Molecule for Atopic Dermatitis - Drug Profile 165 coagulation factor XIVa (human) - Drug Profile 166 NCX-1047 - Drug Profile 167 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
S-414114 - Drug Profile 168 SWT-01113 - Drug Profile 170 SWT-05141 - Drug Profile 171 Small Molecule to Antagonize PAR-2 for Atopic Dermatitis, Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile 172 RTU-1096 - Drug Profile 173 P-529 - Drug Profile 174 CIR-001 - Drug Profile 176 LEKTI-6 - Drug Profile 177 MLR-1130 - Drug Profile 178 A-3914 - Drug Profile 179 SIG-1311 - Drug Profile 180 C-21 - Drug Profile 181 RS-1269 - Drug Profile 183 SUN-0597 - Drug Profile 184 PAC-14028 - Drug Profile 186 CCX-6239 - Drug Profile 188 BBI-2111 - Drug Profile 189 NPB-3 - Drug Profile 190 HS-378 - Drug Profile 191 A-5425 - Drug Profile 192 betamethasone dipropionate - Drug Profile 193 Q-301 - Drug Profile 194 CDE-001 - Drug Profile 195 ARN-077 - Drug Profile 196 TKM-0150 - Drug Profile 197 ARGX-112 - Drug Profile 198 VTP-38543 - Drug Profile 199 AN-3485 - Drug Profile 200 PMA-101R - Drug Profile 201 PMA-201 - Drug Profile 202 PMA-411R - Drug Profile 203 FB-825 - Drug Profile 204 NPH-12 - Drug Profile 205 triamcinolone acetonide - Drug Profile 206 clobetasol propionate - Drug Profile 207 FP7 Project - Drug Profile 208 ANB-020 - Drug Profile 209 LCB-030110 - Drug Profile 210 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
N-Acylethanolamine Acid Amidase Inhibitors for Chronic Inflammation and Atopic Dermatitis Drug Profile 211 P-10 - Drug Profile 212 WF-10 - Drug Profile 213 PL-601 - Drug Profile 215 Drug for Atopic Dermatitis - Drug Profile 216 FIB-116 - Drug Profile 217 Synthetic Peptide to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders Drug Profile 218 BB-2702 - Drug Profile 219 Small Molecule for Atopic Dermatitis - Drug Profile 220 Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 221 Atopic Dermatitis - Recent Pipeline Updates 222 Atopic Dermatitis - Dormant Projects 258 Atopic Dermatitis - Discontinued Products 265 Atopic Dermatitis - Product Development Milestones 266 Featured News & Press Releases 266 Appendix 274 Methodology 274 Coverage 274 Secondary Research 274 Primary Research 274 Expert Panel Validation 274 Contact Us 275 Disclaimer 275 List Of Tables Number of Products under Development for Atopic Dermatitis, H2 2014 18 Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 21 Number of Products under Development by Companies, H2 2014 (Contd..1) 22 Number of Products under Development by Companies, H2 2014 (Contd..2) 23 Number of Products under Development by Companies, H2 2014 (Contd..3) 24 Number of Products under Development by Companies, H2 2014 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H2 2014 26 Comparative Analysis by Late Stage Development, H2 2014 27 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Comparative Analysis by Clinical Stage Development, H2 2014 28 Comparative Analysis by Early Stage Development, H2 2014 29 Products under Development by Companies, H2 2014 30 Products under Development by Companies, H2 2014 (Contd..1) 31 Products under Development by Companies, H2 2014 (Contd..2) 32 Products under Development by Companies, H2 2014 (Contd..3) 33 Products under Development by Companies, H2 2014 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2014 35 Atopic Dermatitis - Pipeline by Bristol-Myers Squibb Company, H2 2014 36 Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2014 37 Atopic Dermatitis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 38 Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 39 Atopic Dermatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 40 Atopic Dermatitis - Pipeline by Merck & Co., Inc., H2 2014 41 Atopic Dermatitis - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 42 Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 43 Atopic Dermatitis - Pipeline by Novartis AG, H2 2014 44 Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2014 45 Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 46 Atopic Dermatitis - Pipeline by Eisai Co., Ltd., H2 2014 47 Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2014 48 Atopic Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 49 Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2014 50 Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2014 51 Atopic Dermatitis - Pipeline by Bayer AG, H2 2014 52 Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2014 53 Atopic Dermatitis - Pipeline by NicOx S.A., H2 2014 54 Atopic Dermatitis - Pipeline by Nuvo Research Inc., H2 2014 55 Atopic Dermatitis - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 56 Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 57 Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 58 Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2014 59 Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 60 Atopic Dermatitis - Pipeline by R-Tech Ueno, Ltd., H2 2014 61 Atopic Dermatitis - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 62 Atopic Dermatitis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 63 Atopic Dermatitis - Pipeline by Foamix Ltd., H2 2014 64 Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2014 65 Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2014 66 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Atopic Dermatitis - Pipeline by IMMD Inc., H2 2014 67 Atopic Dermatitis - Pipeline by Circassia Holdings Ltd., H2 2014 68 Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2014 69 Atopic Dermatitis - Pipeline by Melior Discovery, Inc., H2 2014 70 Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 71 Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2014 72 Atopic Dermatitis - Pipeline by Welichem Biotech Inc., H2 2014 73 Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2014 74 Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2014 75 Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2014 76 Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2014 77 Atopic Dermatitis - Pipeline by Promius Pharma, LLC, H2 2014 78 Atopic Dermatitis - Pipeline by Celsus Therapeutics Plc, H2 2014 79 Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2014 80 Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2014 81 Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 82 Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2014 83 Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2014 84 Atopic Dermatitis - Pipeline by Pergamum AB, H2 2014 85 Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2014 86 Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2014 87 Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2014 88 Atopic Dermatitis - Pipeline by Herantis Pharma plc., H2 2014 89 Atopic Dermatitis - Pipeline by Creabilis SA, H2 2014 90 Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2014 91 Atopic Dermatitis - Pipeline by Dermira Inc., H2 2014 92 Atopic Dermatitis - Pipeline by Istituto Italiano di Tecnologia, H2 2014 93 Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2014 94 Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2014 95 Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2014 96 Assessment by Monotherapy Products, H2 2014 97 Number of Products by Stage and Target, H2 2014 100 Number of Products by Stage and Mechanism of Action, H2 2014 104 Number of Products by Stage and Molecule Type, H2 2014 110 Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H2 2014 228 Atopic Dermatitis - Dormant Projects, H2 2014 264 Atopic Dermatitis - Dormant Projects (Contd..1), H2 2014 265 Atopic Dermatitis - Dormant Projects (Contd..2), H2 2014 266 Atopic Dermatitis - Dormant Projects (Contd..3), H2 2014 267 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Atopic Dermatitis - Dormant Projects (Contd..4), H2 2014 268 Atopic Dermatitis - Dormant Projects (Contd..5), H2 2014 269 Atopic Dermatitis - Dormant Projects (Contd..6), H2 2014 270 Atopic Dermatitis - Discontinued Products, H2 2014 271 List Of Figures Number of Products under Development for Atopic Dermatitis, H2 2014 18 Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2014 19 Number of Products under Development by Companies, H2 2014 20 Number of Products under Investigation by Universities/Institutes, H2 2014 26 Comparative Analysis by Late Stage Development, H2 2014 27 Comparative Analysis by Clinical Stage Development, H2 2014 28 Comparative Analysis by Early Stage Products, H2 2014 29 Assessment by Monotherapy Products, H2 2014 97 Number of Products by Top 10 Target, H2 2014 98 Number of Products by Stage and Top 10 Target, H2 2014 99 Number of Products by Top 10 Mechanism of Action, H2 2014 102 Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 103 Number of Products by Top 10 Route of Administration, H2 2014 106 Number of Products by Stage and Top 10 Route of Administration, H2 2014 107 Number of Products by Top 10 Molecule Type, H2 2014 108 Number of Products by Stage and Top 10 Molecule Type, H2 2014 109
Report Price: Licence Type
Price
$ 2000
Site Licence
$ 4000
Enterprise Wide Licence
$ 6000
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Related Reports: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2014 Cervical Cancer - Pipeline Review, H2 2014 Gastric Motility Disorder - Pipeline Review, H2 2014 Iron Deficiency Anemia - Pipeline Review, H2 2014 Hospital Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014 Chronic Cough - Pipeline Review, H2 2014 Dystonia - Pipeline Review, H2 2014 Lyme Disease - Pipeline Review, H2 2014 Streptococcus Pyogenes Infections - Pipeline Review, H2 2014 Infections Caused By Picornaviridae - Pipeline Review, H2 2014
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Atopic Dermatitis - Pipeline Review, H2 2014 http://www.jsbmarketresearch.com/healthcare-medical/r-Atopic-DermatitisPipeline-Review-H2-2014-124323
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/